Home

PHEX 1 Task Force

Project Leader Leonila F. Dans, MD, MSc Co-Project Leader Antonio L. Dans, MD, MSc Project Manager Ian Theodore G. Cabaluna RPh, MD, GDip (Epi), MSc (cand.) Technical Coordinator Maria Vanessa Villaruz-Sulit, RN, MSc Technical Staff Jamaica Briones, RPh, MSc Administrative Staff Maria Eleanor L. Candelaria, RN, MPH Consensus Panel Meeting Facilitator Bernadette Heizel Manapat-Reyes, MD, MHPEd, FPCP, FPRA Technical Writer Myzelle Anne J. Infantado, PTRP, MSc (cand.) Copy Editor Maria Asuncion A. Silvestre, MD Steering Committee/Lead CPG Developer DANS, Antonio L. MORALES, Dante D. TAMONDONG-LACHICA, Diana HO, Beverly Lorraine C. ESPINA, Aileen R. Evidence Review Experts BAYONA, Howell Henrian G. BRIONES, Jamaica BUROG, Aldrich Ivan Lois D. CABALUNA, Ian Theodore G. DOFITAS, Belen L. DONES, Valentin III C. DY, Louie ESTEBAN-IPAC, Natasha Ann EUBANAS, Gina S. GARCIA, Anna Maria Vida P. GENUINO, Rowena F. INFANTADO, Myzelle Anne J. LEGASPI, Katelyn PALILEO-VILLANUEVA, Lia M. SAN JOSE, Maria Cristina Z. TABULA, Joey A. TATING, Dan Louie Renz P. TOLOSA, Maria Teresa S. YASAY, Eric B. Consensus Panel FERNANDEZ-DE LEON, Japhet G. (Philippine Medical Association) ANDAL, Abigael C. (Philippine Academy of Family Physicians) BAUTISTA, Eva I. (Philippine Pediatric Society, Inc.) DE LEON, Rosie S. (Philippine Nurses Association, Inc) DIOSANA, Jo-Ann L. (Patient advocate) DY-ECHO, Ana Victoria (Philippine Obstetrical and Gynecological Society Foundation, Inc.) TIANGHA-GONZALES, Jeanne (Association of Municipal Health Officers of the Philippines) LIBRADO, Dax Ronald O. (Philippine Society of General Internal Medicine) MOMVILLE, Jacqueline Frances F. (Philippine Society of Public Health Physicians) NICODEMUS, Nemencio Jr. (Philippine College of Physicians) TABUN, Arnold P. (Philippine College of Occupational Medicine) VELASCO, Gloria Nenita V. (DOH-HPDPB-HRD)

PHEX 2 Task Force on Screening for Cardiovascular Diseases

Steering Committee Chair - Felix Eduardo R. Punzalan, MD Co-Chair: Jose Donato A. Magno, MD Deborah Ignacia D. Ona, MD Jean Alcover-Banal, MD John Dennis B. Alcaraz, MD Technical Coordinator Raymond V. Oliva, MD Evidence Review Experts Elmer Jasper B. Llanes, MD Eddieson M. Gonzales, MD Luigi Pierre S. Segundo, MD Bevy Lynn C. Leano, MD Mark A. Vicente, MD Farrah Haidee Lynne D. Pedracio, MD Elaine B. Alajar, MD Noemi S. Pestaño MD Jaime Alfonso M. Aherrera, MD Consensus Panel Maria Elinore Alba-Concha, MD (PAFP) Danilo F. Baldemor, MD (PCP) Lourdes Ella G. Santos, MD (PHA) Alejandro V. Pineda, MD (PMA) Maria Carissa P. Franks, MD (PNA) Carmela Rosanne A. Remotigue, MD (PSGIM) Alberto A. Atilano, MD (PSH) Rex Vener P. Palma, MD (PSVM) Grace V. Buot (Pt Rep) Melvin D. Miranda, RN (PNA) Maria Rosario Sylvia Uy, MD (DOH) Technical Writer Raymond V. Oliva, MD Technical Facilitator Carlo Irwin Panelo, MD Administrative Officer Princess Marie T. Sulit, RN

PHEX 2 Task Force on Screening for Neoplastic Diseases

Steering Committee Chair: Beatrice J. Tiangco, MD, MSc Co-chair: John Q. Wong, MD, MSc Jericho Thaddeus P. Luna, MD Manuel Francisco Tañada Roxas, MD Madeleine de Rosas-Valera, MD Technical Coordinator Aldrich Ivan Lois D. Burog, MD Evidence Reviewer Howell Henrian G. Bayona Rogelio N. Velasco Jr., MD Aldrin B. Loyola, MD Mary Ondinee Manalo Igot, MD Ann Meredith Garcia-Trinidad, MD Kenneth G. Samala, MD Ma. Pamela D. Patdu, MD Jezreline Marie I. Cacanindin-Rimando, MD Myzelle Anee J. Infantado Gina Antonina S. Eubanas, MD Consensus Panel Josefina A. Tuazon, MD (DOH-HTAC) Ma. Cecilia P. Paje, MD (PONA) Heinrik Martin Jude S. Strebel, MD (PSMO) Katrina G. Gomez, MD (PSPHP) Marcia Feria Miranda (Pt Rep) Clarito U. Cairo Jr. (DOH) Maria Julieta V. Germar, MD (POGS) Catherine S.C. Teh, MD (PCS) Nemencio A. Nicodemus Jr, MD (PCP) Misael C. Cruz, MD (PCR) Jeffrey S. So, MD (PSP) Technical Writer Isabel Teresa Salido Technical Facilitator Maria Asuncion A. Silvestre, MD Admin. Officer Leo M. Flores

PHEX 2 Task Force on Screening for Congenital & Developmental Disorders

Steering Committee Chair: Mary Ann R. Abacan, MD Co-Chair: Angelica Cecilia V. Tomas, MD Mary Anne D. Chiong, MD Anna Guia O. Limpoco, MD Maria Isabel O. Quillendrino, MD Technical Coordinator Kathryn R. Baltazar-Braganza, MD Evidence Reviewer Melissa A. Dator, MD Fides Roxanne M. Castor, MD Grazielle S. Versoza, MD Vaneza Leah A. Espino, MD Corinna Victoria M. Puyat, MD Reginald B. Balmeo, MD Marc Andrew O. Perez, MD Ma. Margarita S. De Rivera, MD Christine Mae S. Avila, MD Charlotte Averill Y. Tan, MD Mario Lorenzo Bautista, MD Hazel S. Baconga, MD Liza Marie P. Bejemino, MD Ma. Theresa M. Collante, MD Natasha Ann R. Esteban-Ipac, MD Erena S. Kasahara, MD Marie Julianne C. Racoma, MD Consensus Panel Hairam R. Encendencia, MD (AMHOP) Benjamin P. Sablan Jr., MD (PAPA) Janet Marianne Go-Nierva, MD (PPS) Maria Melanie B. Alcausin, MD (Geneticist) Cindy C. Llego, MD (PSDBP) Abigael C. Andal-Saniano, MD (PAFP) Maria Socorro L. Romabiles, MD (Social Scientist) Maria Wilda T. Silva, MD (DOH) Florence B. Nitafan (HAPI) Martin Graciano Raymundo S. Baquiran, MD (CEAP) Technical Facilitator Carlo Irwin A. Panelo, MD Technical Writer Isabella S. Ocampo, MD Admin. Officer Claudette V. Silva

PHEX 2 Task Force on Screening for Mental Disorders & Substance Abuse

Steering Committee Chair: Shelley Anne D. De La Vega, MD Co-Chair: Marc Evans M. Abat, MD Belen E. Mojares-Dimatalac, MD Edwin M. Fortuno, MD Jose Paciano Baltazar T. Reyes, MD Technical Coordinator Angely P. Garcia Evidence Reviewer Mark Dale S. Imbag, MD Josemaria F. Lopez, MD Ayra Mae S. Balingbing, MD Maverick Tyrone A. Jacalan, MD Andrea Victoria Eireen M. Castro, MD Hannah M. Pellejo, MD Joy Marie A. Gillera, MD Kenneth Brian B. Lim, MD Krisha Mae C. Borromeo, MD Ma. Rosario Jacinta F. Lopez, MD Consensus Panel Emmanuel V. Hernani, MD (PAP) Jennifer Justice F. Manzano, MD (PNA) Lourdes Carolina I. Dumlao, MD (PCGM) Salvador Benjamin D. Vista, MD (Addiction Psychiatry) Maria Eliza R. Aguila (UP CAMP) Mario Narciso A. Marcelo, MD Mary Dawn dela Cruz Robert D. Buenaventura, MD (PPA) Alfon Guiller D. Daga (PNA) Viel Delos Santos-Mendoza, (ADAP) Venus S. Arain, MD (PMHA) Francisca Rosario B. Espino-Tan (PCGM) Agnes Casino, MD (DOH-DPCB) Technical Facilitator Lia Aileen M. Palileo-Villanueva, MD Technical Writer Christine A. Dator, MD Admin. Officer Tyrone Jann R. Flores

PHEX 2 Task Forces on Immunization

A. PEDIATRICS Steering Committee Chair: Marimel R. Pagcatipunan, MD Charissa Fay Corazon B. Tabora, MD Mary Antonette C. Madrid, MD Technical Coordinator Carol Stephanie Tan-Lim, MD Evidence Reviewer Michelle Cristine B. Miranda, MD John Andrew T. Camposano, MD Francesca Mae T. Pantig, MD Sarah R. Makalinaw, MD Zaira Nina T. De Leon, MD Reginald B. Balmeo, MD Angeli W. Wyson-Wong, MD Consensus Panel Rosemarie T. Santana-Arciaga, MD (PIDSP) Cynthia Alcantara-Aguirre, MD (PIDSP) Benjamin P. Sablan, MD (PPS/Adolescent Medicine) Melissa Joyce Ramboanga, MD (PAPA) Philline Aura Grace S. Salvador, MD (PSPHP) Marysia Stella P. Tiongco-Recto, MD (PSAAI) Teri Marie P. Laude, MD (PAFP-Family Physician) Cerelyn Evangelista-Dacula, MD Kim Patrick S. Tejano, MD (DOH-DPCB) Expedito T. Yala, MD (PFV) Technical Facilitator Mayan Uy-Lumandas, MD Technical Writer Angelie M. Wyson-Wong, MD Assistant Administrative Officer Jonalyn Nuqui B. ADULT Steering Committee Chair: Rosally P.Zamora, MD Roberto A. Razo II, MD Jane Eflyn Lardizabal-Bunyi, MD Technical Coordinator Howell Henrian G. Bayona Evidence Reviewer Aldrich Ivan Lois D.Burog, MD Kathryn U. Roa, MD Mithi Kalayaan S. Zamora, MD Carol Stephanie Tan-Lim, MD Renee Anne Karmela L. Feliciano, MD Isabel Kristine M. Valdez, MD Sean Kendrich Cua, MD Jonathan Chan Jeriel De Silos, MD Consensus Panel Hairam R. Encendencia, MD (AMHOP) Ma. Charmian M. Hufano, MD (PSMID) Mario M. Panaligan, MD (PCP) Marishiel Mejia-Samonte, MD (PAFP) Joannah Kaye Borallo, MD (DOH) Kim Patrick S. Tejano , MD (DOH) Imelda Asetre-Luna, MD (PPS) Ruperto Angel O. Navarro, MD (Occ. Med) Technical Facilitator Bernadette Heizel M. Reyes, MD Technical Writer Aubrey Melody Rocimo Admin. Officer- PEDIA & ADULT Immunization Cynthia C. Lati

PHEX 2 Task Force on Lifestyle Advice

Steering Committee Chair: Diana Tamondong-Lachica, MD Co-Chair: Miriam Roxas-Timonera, MD Jacqueline Frances F. Momville, MD Josefina Isidro-Lapena, MD Rodley Desmond Daniel M. Carza, MD Technical Coordinator Lia Aileen Palileo-Villanueva, MD Evidence Reviewers Jairus Cabajar, MD Johannes Paolo B. Cerrado, MD Blessie Marie B. Perez, MD Patricia Maria Gregoria M. Cuaño, MD Aila Marnelle A. Cruz, MD Eric B. Yasay, MD Marie Gene D. Cruz, MD Lea Roselle De Castro, MD Greco Mark B. Malijan, MD John Jefferson V. Besa, MD John Christopher A. Pilapil, MD Ian Theodore Cabaluna, MD Consensus Panel Joey Francis B. Hernandez, MD (PSPHP) Alisa Bona A. Ascutia, MD (PPS) Diana Alcantara-Payawal, MD (PCP) Reynold M. Sta. Ana (PCOM) Abigail Andal-Saniano, MD (PAFP) Dominic A. Maddumba, MD (DOH) Janice A. Atienza, MD (PSGIM) Einstein C. Rojas (PAPO) Jeanne V. Tiangha-Gonzales, MD (AMHOP) Michelle Anne Noblejas- Mangubat, MD (PSAMS) Melbert B. Reyes, RN (PNA) Technical Facilitator Elenore Judy B. Uy, MD Technical Writer Cary Amiel G. Villanueva, MD Admin. Officer Charissa Rosamond D. Calacday, RN, MAN

PHEX 3 Task Force on Screening for Hearing Disorders

Steering Committee Members: Ryner Jose D. Carrillo, MD, MSc (Chair) Abigail S. Salcedo, MD (Co-chair) Lina Rose A. Alcances, MD, MOH, FPSOHNS Jose Leonard R. Pascual V, MD, FPNA Technical Coordinator: Kathryn R. Baltazar-Braganza, MD, FPPS, FPSDBP Evidence Review Experts:: Aubrey Melody Rocimo, MD Karl Jeffrey E. Murillo, MD Marie Gene D. Cruz, MD Mark Dale Imbag, MD Theresa M. Collante, MD, FPPS, FPRA, CCD Charlotte Averill Y. Tan, MD, DPPS Michelle Anne Noblejas-Mangubat, MD, FPPS, FPSAMS Marquis Von Angelo Syquio G. Joson, MD Ma. Kriselda P. Alonzo, MD, DPPS Consensus Panelists: Larissa Christia F. Adique, MClAud Abigael C. Andal-Saniano, MD, FPAFP Jaymilyn V. Catangay-Ombao, MClinAud Ma. Teresita S. Cucueco, MD, MOH Joanna Sebastiana M. De Ramos, MD, DHPEd, FPSO-HNS Elmer M. Dela Cruz, MD, MClAud, FPSO-HNS, FPCS Jan Alexeis Lacuata, MD Cindy C. Llego, MD, FPPS, FPSDBP Kimberly Mae C. Ong, MD, FPSO-HNS Hubert dela Cruz Ramos, MClAud Maria Rina T. Reyes-Quintos, MD, PhD, FPSO-HNS Rosario R. Ricalde, MD, FPCS, FPSO-HNS Talitha Karisse L. Yarza, MClAud Consensus Panel Meeting Facilitator: Carlo Irwin A. Panelo, MD, MA External Reviewers: Philip B. Fullante, MD, FPSOHNS Ma Leah C. Tantoco, MD, FPSOHNS Rodante A. Roldan, MD, MHA, FPSOHNS Technical Writer: Abigail S. Salcedo, MD Administrative Officer: Claudette V. Silva

PHEX 3 Task Force on Screening for Musculoskeletal Disorders

Steering Committee: Evelyn O. Salido, MD, MSc (Chair) Ranali Mendoza, MD (Co-Chair) Bernadette Heizel Reyes, MD, MHPED Nathaniel Orillaza, MD Carl Leochico, MD Technical Coordinator: Ivan Burog, MD Evidence Review Experts: Howell Henrian G. Bayona, RSLP, MSc Kerwyn Jim C. Chan, RSLP, Msc Vaneza Leah A. Espino, MD, FPPS, DPAPP Mark David Francisco, MD, FPCP, FPCEDM Myzelle Anne J. Infantado, PTRP, MSc (cand) Rich Ericson C. King, MD, FPCP, DPSMO Cary Amiel G. Villanueva, MD, MPH Mithi Kalayaan S. Zamora, MD, FPCP, FPCCP Consensus Panelists: Zenaida Aquino Christine B. Bernal, MD, FPPS, FPRA Amanda Glenda M. Bonife-Kiamko Ma. Teresita S. Cucueco, MD, MOH, FPCOM Myrna S. Estrada, MD, MBA, FPARM, DPCOM Ivy Catherine Rivera-Go, MD, FPCP, FPRA Cheridine P. Oro- Josef, MD, MMHoA, FPAFP, FPCGM Ma. Zaela Vanessa M. Mailom, MD, DPCOM, FPAPSHI Robert Matthew A. Marquez, MAN, RN Kenneth Charles V. Mutia, PTRP Ameena Tara X. Santos, MD, FPOA Reynold Sta. Ana, MD, MOH, FPCOM Endrik H. Sy, MD, FPAFP External Reviewers: Ruth Padua, MD, FPOA (Ortho) Sandra Torres, MD, FPCP, FPRA (Rheuma) Jose Alvin Mojica, MD, MHPED, FPARM (Rehab) Facilitator: Diana Tamondong-Lachica, MD, FPCP Technical Writer: Isabel Teresa O. Salido Administrative Officer: Ma. Caroline Peralta, DMD

PHEX 3 Task Force on Screening for Infectious Diseases

Task Force Steering Committee Chair/Co-chairs: Jemelyn U. Garcia, MD Rosally Zamora, MD Members: Diana Payawal, MD Anna Sofia Victoria Fajardo, MD Abigael Andal-Saniano, MD Technical Working Group Technical Coordinator: Christopher G. Manalo, MD, MSc (cand), FPCEM Evidence Review Experts Kenny Jun N. Demegillo, MD Elaine Dawn C. Butron, MD Mark Dale S. Imbag, MD Michelle Cristine B. Miranda, MD Frangelo Condrad P. Tampus, MD Erika A. Crisostomo, MD Anna Maria Vida P. Garcia, RPh, D Clin Epi Maria Cristina H. Lozada, MD Lea Roselle O. De Castro, MD Ron Rafael Gabunada, MD Consensus Panel Geannagail O. Anuran, MD Ian Homer Cua, MD Jacqueline Frances F. Momville, MD Reynaldo San Luis, MD Ronald M. Panaligan, MD Mr. Christopher Muñoz Rogelio Dazo, Jr., MD Thea Pamela Cajulao, MD Juan Maria Ibarra Co, MD Gerard Danielle K. Sio, MD Consensus Panel Meeting Facilitator: Cary Amiel Villanueva, MD Technical Writer: Jennel Mae T. Pimentel Administrative Officer: Rhea Pablo-Anwar, RN

PHEX 3 Task Force on Screening for Prenatal Disorders

Task Force Steering Committee Chair: Dr. Maria Julieta V. Germar Members: Dr. Betha Fe M. Castillo Dr. Ma. Susan B. Villaluz Dr. Potre Mairasna P. Boransing Dr. Sherri Ann L. Suplido Dr. Mike Justin Agustin Gianan Dr. Endrick H. Sy Dr. Maria Theresa G. Cacas Dr. Helen B. De Peralta-Yambao Technical Facilitator: Dr. Maria Asuncion A. Silvestre Technical Working Group Technical Coordinator: Dr. Lia Aileen M. Palileo-Villanueva Evidence Review Experts Dr. Cary Amiel Villanueva Dr. Lea de Castro Dr. John Jefferson Besa Dr. Ella Mae Masamayor Dr. Andrew Rufino Villafuerte Dr. Johannes Paolo Cerrado Dr. Marie Gene Cruz Dr. Greco Mark Malijan Dr. Ma. Sergia Fatima Sucaldito Consensus Panel Dr. Kristine Elises-Molon – POGS Dr. Clarissa Velayo – PSMFM Dr. Alfonso Yoshida – PAFP Dr. Lester Sam Geroy – PSPHP Ms. Elvie Estrada – IMAP Dr. Daisy Evangeline Garcia – PSNM Dr. Ferdinand Sta. Ana – Primary Care Providers-DTTB Dr. Karla Kristine Fernando – PSEM Dr. Lara Bustamante – PSUOG Ms. Jo-Ann Diosana – Patient Advocate DOH Representative: Dr. Ysa Gonzales-Andres Technical Writer: Ms. Hygeia Grace C. Agosto Administrative Officer: Ms. Princess T. Sulit

PHEX 3 Task Force on Screening for Renal, Metabolic, Nutritional, and Endocrine Disorders

Steering Committee Chair: Elizabeth Paz-Pacheco, MD Steering Committee Co-chair: Raymond Oliva, MD Steering Committee Members: Cecilia Santos-Acuin, MD Rey Jaime Tan, MD Technical Coordinator: Raymond Oliva, MD Evidence Review Experts: Ma. Czarlota Acelejado-Valdenor, MD Janika Adrienne Balane, MD Rommel Bataclan, MD Agnes Baston, MD Antonio Faltado, Jr., MD Katrina Gomez-Chua, MD Anna Angelica Macalalad-Josue, MD Anna Francesca Mulles, MD Karl Jeffrey Murillo, MD Sahra May Paragas, MD Chona Patalen Rogelio Velasco, Jr., MD Scientific Writer: Jim Paulo Sarsagat, MD Consensus Facilitator: Carlo Irwin Panelo, MD Consensus Panel: Jeanne Tiangha-Gonzales, MD (AMHOP) Charmaine Duante (DOST-FNRI) Olive Quizon, MD (PAFP) Catherine Danielle Duque-Lee, MD (PAFP) Marimel Lamsin (PAPO) Maria Theresa Talavera, RND, DrPH (PAN) Emelita Ong-Lavilla, RND, MHA (PAN) Daveric Pagsisihan, MD (PCEDM) Danilo Baldemor, MD (PCP) Vimar Luz, MD (PSN) Administrative Officer: Maria Rhodora Aquino

PHEX 3 Task Force on Screening for Vision Disorders

Steering Committee: Carlos Garcia Naval, MD (chair) Shelley Ann M. Mangahas, MD (co-chair) Alex Bienvenido J. Alip, Jr., MD Ma. Olive P. Lazo, MD Chandru P. Pessumal, O.D. Consensus Panel: Beltran Alexis Aclan, MD, MHCM Christine Anne Corazon Arreola-Lamorena, MD Catherine Guzman-Asio, MD Rommel Hernandez, MD, CFP, MHA Nancy Ilagan Regino Mallari, RN, LPT Marvin Masalunga, MD, MPM Andrea Kristina Pajarillo, MD Anna Maria Roqueza Winona Sevilla-Pasimio, PhD Neal Vicente Torres, MD Evidence Review Experts: James Paul Gomez, MD Kenneth Brian Lim, MD Kristine Marie Lim, RN Josemaria Lopez, MD Ma. Rosario Jacinta Lopez Carol Tan-Lim, MD Technical Coordinator: Aldous De Leon, MD Technical Facilitator: Sandra Torres, MD Technical Writer: Joy Gillera Isabel Teresa Salido Administrative Officers: Noleen Marie Fabian

PHEX 3 Task Force on Adult Immunization

Task Force Chair: Armin N. Masbang, RMT, MD, FPCP, FPSMID Technical Coordinator: Howell Henrian G. Bayona, MSc Steering Committee Members: Rosally P. Zamora, MD, FPCP, FPSMID Jane Effyn Lardizabal-Bunyi, RPh, MD, OHP, DFM, FPAFP, CSPSH Roberto A. Razo II, MD, FPSP, FPCP Rommel B. Punongbayan, MD, MBA, FPCP, DPCOM, CSPSH Consensus Panel Members: Elmer Bondoc, MD Edmyr Macabulos, MD Hairam Encendencia, MD Rupert Angel Navarro, MD Marishiel Samonte, MD Mariou Claris, RPh Charmaine Hufano, MD James Dela Cruz, MD Imelda Luna, MD Evidence Review Experts: Aubrey Melody Rocimo, MD Aldrich Ivan Lois Burog, MD Bernard Demot, MD Gina Antonina Eubanas, MD Honey Jane Limos, MD Kerwyn Jim Chan, MSc Mithi Kalayaan Zamora, MD Myzelle Anne Infantado Samantha Bartolo, MD Timothy Hudson David Carandang, MD Vanezah Leah Espino, MD Consensus Panel Meeting Facilitator: Bernadette Heizel D. Manapat-Reyes, MD, MHPEd Technical Writer: Alrenzo Ludwig Domingo, MD Administrative Officer: Carlos Diego A. Rozul

PHEX 3 Task Force on Pediatric Immunization

Task Force Steering Committee Chair: Marimel G. Reyes-Pagcatipunan, MD, FPPS, FPIDSP Co-Chair : Carmina A. Delos Reyes, MD, FPPS,FPIDSP Members: Mary Antonette C. Madrid, MD, FPPS, FPIDSP Charissa Fay Corazon C. Borja-Tabora, MD, FPPS, FPIDSP Melody Kiat Tolentino. MD, DPPS, DPIDSP Technical Working Group Technical Coordinator: Natasha Ann R. Esteban-Ipac, MD, FPPS, DPSAMS Evidence Review Experts: Kia S. Anarna, MD Reginald B. Balmeo, MD John Andrew T. Camposano, MD Fides Roxanne M. Castor-Racelis, MD Patricia Marie D. Isada, MD Michelle Cristine B. Miranda, MD April P. Padua-Zamora, MD Francesca Mae T. Pantig, MD Frangelo Conrad P. Tampus, MD Paul Sherwin O. Tarnate, MD Consensus Panel: Cynthia Alcantara-Aguirre, MD, FPPS, FPIDSP, PFV Rosemarie T. Santana-Arciaga, MD, FPPS, FPIDSP, PIDSP Mary Ann Bunyi, MD, FPPS, FPIDSP, PIDSP Teri-Marie Laude, MD, MsCM-FM, PAFP Melissa Joyce Ramboanga, MD, PAPA Marysia Stella P. Tiongco-Recto, MD, PSAAI Maria Teresa D. Villanueva, MD, FPPS, PPS Maria Lourdes Bernadeth V. Manipon, RN, PHICNA Bryan S. Posadas, RPh, PPAI Panel Meeting Facilitator: Mary Ann Abacan, MD, FPPS Technical Writer: Korina Ada D. Tanyu, MD, FPPS Administrative Officer: Jonalyn N. Nuqui

Please fill up the fields below.

Search
Specific Details

Age

Sex

Male
Female

Height

Weight

BMI

Smoking History

Yes
No

Sexual Activity

Yes
No

Pregnant

Yes
No

Search by
Specific File

These guidelines are intended for use of primary care providers.

Disclaimer Who We Are About PHEX

Introduction Methodology Conflict of Interest

This guideline is intended to be used by general practitioners, specialists and health professionals who are primary care providers. Although adherence to this guideline is encouraged, it should not restrict the primary care providers in using their sound clinical judgment in handling individual cases. Payors and policymakers, including hospital administrators and employers, can also utilize this CPG, but this document should not be the sole basis for evaluating insurance claims. Recommendations from the PHEX app and the guidelines therein should also not be treated as strict rules on which to base legal action.

Central Steering Commitee
Program Leaders Leonila F. Dans, M.D., M.Sc Marissa M. Alejandria, M.D., MSc Central Steering Committee Members Antonio Miguel L. Dans, M.D., M Sc Dante D. Morales, M.D. Beverly C. Ho, M.D Aileen Espina, M.D. Maria Vanessa V. Sulit, RN, M Sc Diana Lachica Tamondong M. D. Project Managers Ian Theodore G. Cabaluna, R.Ph., M.D., Gdip(ClinEpi) Josephine T. Sanchez, RN Administrative Staff Maria Pamela A. Tagle Lailanie Ann C. Tejuco Jorge Romero OVERSIGHT COMMITTEE (OC) Chair: Dr. Dante D. Morales Co-Chair: Antonio Miguel L. Dans Angela Abanilla-Du, MD Camilo G. Te, MD Maria Vanessa Villaruz-Sulit, RN, MSc

Preventive health screening has been advocated as a means to improve health outcomes and quality of life, and avoid preventable deaths. However, despite its perceived benefits, it may also bring harm to a patient such as physical, emotional and financial consequences of false positive results and more importantly, overdiagnosis. The “Philippine Guidelines on Periodic Health Examination (PHEX): Effective Screening for Diseases Among Apparently Healthy Filipinos” was developed in 2004 to guide health providers and patients on preventive health screening. As new evidence on preventive screening emerges and the enactment of the Universal Healthcare law, there is an urgent need to update the existing outdated guidelines. Due to the large scope of the guideline, its updating was carried in 3 phases. Phase 1 entailed evaluation of select screening strategies that are currently being implemented by the Department of Health. Phase 2 and 3 involved evaluation of additional screening strategies, that are considered novel, controversial, or misused. Phase 2 also involved the development of an online and mobile app that will allow users to generate a patient-specific plan based on age, sex, risk factors, and other patient characteristics. It covered screening recommendations for cardiovascular, neoplastic, congenital disorders, mental health & substance abuse, lifestyle advice and immunizations. The recommendations in this website covers Phase 1 & 2 of the project.

The general CPG methodology used for the entire update was the GRADE approach, following the recommended process in the DOH Manual on Practice Guideline Development. The target users of the CPG would be primary care providers and policymakers. The target population of the screening test and interventions was the apparently healthy asymptomatic Filipinos. Guideline Preparation PHEX Phase 1 & 2 convened a Central Executive Committee comprised of a Steering Committee (SC), Oversight Committee (OC) and Central administrative staff. Phase 1 : Konsulta Package screening interventions Phase 2: Six task forces (TF) were convened to develop their respective guidelines namely: 1. Task force on Screening for Cardiovascular Disease 2. Task Force on Screening for Neoplastic Diseases 3. Task force on Screening for Congenital and Developmental Disorders 4. Task Force on Screening for Mental Disorders and Substance Abuse 5. Task Force on Immunization – Pediatric & Adult 6. Task Force on Screening on Lifestyle Advise Task Force chairs were identified to lead each TF. They identified and recruited the working committees namely: 1) Task force SC, 2) Technical Working Group (technical coordinator, evidence review experts, technical writer, technical meeting facilitator, and an administrative officer) 3) Consensus Panel (CP) members. Each task force Steering Committee prioritized and finalized the guideline questions to be addressed, 2) convened the ERE and 3). convened the CP. 4). supervised the entire CPG process. Additional methods done by each task force are found in their respective manuscripts. Due to the number of task forces involved in the project, a Central Executive Committee, led by Dr. Leonila F Dans and Dr. Marissa A Alejandria, was created. The team was composed of the central steering committee, project leaders (LFD, MMA), project managers and administrative staff. The team oversaw and coordinated with all task forces. The Central Executive Committee provided continuous administrative and technical support to the task forces including the collection of declaration of Conflict of Interest, Curriculum Vitae (CVs), preparation, collection and processing of contracts and other salary/honorarium documents, training of task force members, and technical guidance throughout the whole CPG development process. The central team ensured that the CPG methodology as recommended in the DOH Manual for CPG Development was followed. The team guided and reviewed the development of research questions and evidence summaries. Lectures, instruction modules, technical resource and templates were prepared to guide the task force in developing the research questions, evidence synthesis, and facilitation of CP meetings. Online orientation on CPG methodology tasks, specific steps were given to the task force steering committee, technical writers, evidence reviewers, technical coordinators, and facilitators. Prioritizing the Guideline Research Questions The task forces identified, prioritized and finalized the scope and the guideline research questions. Each question included details on population, intervention, comparator, and outcomes. Additional relevant specifics such as subgroup to be considered and frequency of intervention were also included. They consulted different stakeholders in prioritizing and developing their respective guideline questions. The Central Steering Committee reviewed and approved the guideline questions prior to evidence synthesis. Identification and prioritization of questions were mostly based on the following criteria 1. disease burden 2. public contention 3. cost-effectiveness 4. new evidence 5. potential impact 6. interest of public or care providers 7. variation in care 8. sufficiency of evidence and 9. timeliness. Evidence Synthesis Each task force then convened their technical working group composed of a technical coordinator, evidence review experts (ERE) and technical writer. . At least one ERE was assigned a guideline question to work on supervised and guided by a technical coordinator that also functioned as second reviewer. For each guideline question, the GRADE Adolopment process was used in gathering the evidence. It involved extracting and appraising evidence summaries of high-quality CPGs and adapting them into our own local setting by constructing an Evidence to Decision framework. A systematic search of international CPGs that directly answered the guideline question were done. We included guidelines developed by international guideline developing bodies such as the World Health Organization, the United States Prevention Task Force, the Canadian Task Force on Preventive Healthcare, National Institute for Health Care and Excellence and United Kingdom National Screening Committee Recommendations. Two independent reviewers appraised the CPG using AGREE II tool. Evidence summaries of CPG done from 2015 onward and were deemed to have high quality (AGREE II score > 75) were included. Evidence for questions that were not covered by the above CPGs were systematically searched and appraised. The results of the appraisal of existing CPGs and their evidence summaries determined the need for a systematic search in electronic databases (MEDLINE via PubMed, CENTRAL, Google Scholar) to do de-novo systematic reviews and meta-analysis for each question. Relevant local databases and websites of medical societies were also utilized in the search. Keywords were based on PICO (MeSH and free text) set for each question. The ERE also contacted authors of related articles to verify details and identify other research studies for appraisal, if needed. The ERE appraised the directness, methodological validity, results, and applicability of each relevant article included. The ERE generated evidence summaries for each of the questions. Each evidence summary included evidence on the burden of the problem, and diagnostic performance, benefits, harm, and social and economic impact of the screening test/intervention. RevMan, STATA, and GRADEPro were used for the quantitative synthesis of important clinical outcomes for each question. Source of the evidence would include evidence summaries from pre-identified CPG, systematic reviews, health technology assessment reports, and primary studies such as clinical trials, diagnostic accuracy studies, qualitative studies and cost-effectiveness analysis studies whenever possible or available. The certainty of evidence for the benefit and harm of an intervention was assessed according to Table 1. Over-all certainty of evidence per research question will be the lowest level based on the critical outcomes included in the decision-making. The ERE systematically and exhaustively searched for and provided evidence on the following criteria whenever applicable: • Burden of the problem • Diagnostic performance of the screening test • Benefits and harm of the screening test and/or subsequent management • Economic impact and cost of the screening test • Social and health systems impact of the screening test and/or subsequent management. Relevant evidence that would facilitate in the decision (i.e., cost of screening test, cost-effectiveness studies, qualitative studies for patient values and preferences, accessibility, feasibility, and equity issues) were also included in the evidence summaries. The evidence gathered for each guideline question were also incorporated into the GRADE EtD framework to facilitate the decision-making process. A draft recommendation was formulated prior to the panel meeting. The draft recommendations were formulated based solely on the evidence on the balance between benefits and harm of the screening test and the certainty of the evidence. During this stage of development, each task force had a technical coordinator with expertise on CPG development, Evidence-Based Medicine and Evidence synthesis. The TC supervised the retrieval and appraisal of evidence, ensured methodologic rigor of the process and the accuracy and reliability of data extraction, and the construction of the draft recommendations. They also functioned as second reviewer to ERE. Practice presentations with their respective TF SC and the Central Executive Committee were organized to ensure the validity and quality of the evidence summaries prior to the consensus panel meeting. A technical writer (TW) per task force took charge of collating the ES into an evidence base, ensuring the continuity and flow of the manuscript, standardizing the manuscript format and documenting the Consensus meeting to be included in the CPG manuscript. The TW was also responsible for incorporating the agreed recommendation and consensus issues into the final manuscript. Formulation of Recommendations Prior to CP Meeting Each task force convened a 10-15 multisectoral Consensus panel and identified a technical facilitator who oversaw the deliberation and the consensus process. An online orientation session for the panelists and technical facilitators was conducted to introduce the GRADE CPG methodology, interpretation of evidence summaries, the EtD approach and the formal consensus process. The panelists were asked to study the evidence base of the guideline research questions and asked to answer a set of questions based on the EtD framework for each guideline question. Their answers were summarized and presented during the CP meeting. Outcomes were also rated according to whether they were critical, important but not critical or of low importance for decision making by health care providers and consumers. Only important and critical outcomes were included in the evidence summaries to be considered in the decision-making. A maximum of 7 outcomes were considered and presented. During CP Meeting During the facilitated en banc consensus panel meetings, the key findings of the evidence summaries and draft recommendations were presented for deliberation. The criteria on Evidence to Decision framework on diagnostic tests by the GRADE working group were used. Upon clarification and discussions, the panel voted and arrived at a recommendation. If consensus (75% of total votes) was reached before or on the third round, voting on the strength of the recommendation commenced. The CP arrived at a consensus in recommendations for all 16 questions. The CP considered the balance between harm and benefit, certainty of evidence, costs, acceptability, feasibility, appropriateness, and equity in making the recommendation and its strength. The CP needed to decide on the direction of the recommendation [whether to recommend for or against] and the strength of recommendation [whether weak or strong]. Usually high or moderate certainty of evidence will result into a strong recommendation and low or very low certainty of evidence will lead to a weak recommendation. All meetings were done remotely via Zoom. When no consensus was reached during the remote meetings, modified Delphi approach was used to extend the voting process if additional evidence or issues were introduced that might change the votes to reach a consensus. Strong recommendation means that desirable effects of intervention clearly outweigh undesirable effects, or clearly do not while weak recommendations means that trade-offs are less certain, either because of low quality evidence or because evidence suggests desirable and undesirable effects are closely balanced. In case of discrepant decisions with the certainty of evidence, the CP was asked to explicitly justify the recommendations and this was documented under consensus issues in the final manuscript of the CPG.

Management of Conflict of Interest The Central Executive Committee convened an COI Committee (COIC) whose task was to thoroughly review the declaration of conflict of interest (DCOI) of each of the Task Force members particularly the Consensus Panelists (CP) and make recommendations on how to manage the COI. For TF members with potential significant COIs, the members of the COIC conducted additional investigations with due diligence to ensure the integrity of the CPG process and the final recommendations. All task force members submitted a DCOI and their curriculum vitae (CV) prior to the initiation of guideline development process. The disclosure included a 4-year period of personal potential intellectual and/or financial conflicts of interest (COI). Management of the COI of the Consensus Panel, Technical Coordinators, and Task Force Steering Committees were deliberated and decided by the COI Committee, using the pre-agreed criteria. The COIC decision was then forwarded to the Task Force Steering Committee for appropriate action. The COIC members were invited to attend the CP meetings for due diligence if their recommendations were actually being followed.

View PDF File View PDF File View PDF File

Got any questions? Send us an inquiry. Email Message

Screening Strategy Vaccination Lifestyle Advice

Recommendations for Recommendations Against No Recommendations

Strong recommendation

Strong recommendation means that desirable effects of intervention clearly outweigh undesirable effects.

Test & Disease

Frequency

Target Population

History of Tobacco Smoking

every visit

Male or Female aged 19 years and above

History of Tobacco Smoking

Male or Female ages 13 to 18 years

History of Unhealthy Alcohol Use

every visit

Male or Female aged 19 years and above

Family History of Premature Cardiovascular Disease for Familial Hypercholesterolemia

Male or Female aged 19 years and above

Screening for Developmental Delay

Male or Female infants born preterm

Screening for Developmental Delay

Male or Female infants born with maternal risk factors

Standardized Questionnaire for Autism Spectrum Disorder

Male or Female ages 18 to 24 months

Standardized Questionnaire for Substance Use Disorders

once a year

Male or Female aged 19 years and above

Standardized Questionnaire for Anxiety

once a year

Male or Female aged 19 years and above

Standardized Questionnaire for Depression among Children and Adolescents

twice a year

In individuals aged 10 to 18 years, Male OR Female, we recommend screening for Standardized Questionnaire for Depression among Children and Adolescents

Standardized Questionnaire for Stress

once a year

Male or Female aged 19 years and above

Standardized Questionnaire for Sleep Disturbances/Problems

once a year

Male or Female aged 19 years and above

Screening for Sarcopenia

Annual

Asymptomatic apparently healthy adults ≥60 years old

Fall Risk Evaluation to Screen for Predisposition to Fall

Asymptomatic, apparently healthy older adults ≥60 years old

Screening for Osteoporosis

Asymptomatic, apparently healthy women ≥65 years old

Screening for Prediabetes and Type 2 Diabetes Mellitus

Apparently healthy adults aged 40 years above, or younger if with risk factors

Screening for Nutritional Anemia

Asymptomatic, apparently healthy adults

Screening for Hearing Loss

Asymptomatic apparently healthy children

Measure BP for Hypertension

every year

Male or Female aged 19 years and above

Body Mass Index for Obesity

twice a year

Male or Female aged 19 years and above

Stigmata through Physical Examination for Familial Hypercholesterolemia

Male or Female aged 19 years and above

ENT Screening and Dental Check-Up for Oral Cancer

every 3 years

Male or Female aged 35 years and above.

Screening for Inadequate Physical Activity

Annual

Asymptomatic, apparently healthy adults

Screening for Malnutrition/Undernutrition

Asymptomatic, apparently healthy adults

Clinical Breast Examination for Breast Cancer

every 2 years

Female aged 50 years and above

Fasting Blood Sugar for Diabetes

every year

Male or Female aged 40 years and above with risk factors

Screening for Hepatitis C

High risk asymptomatic, apparently healthy adults

Screening for HIV

High-risk asymptomatic, apparently healthy adolescents and adults

Screening for Syphilis

6-12 months

High-risk asymptomatic, apparently healthy non-pregnant adolescents and adults

FOBT or FIT for Colorectal Cancer

every year

Male or Female aged 50 years and above

Ultrasonography for Abdominal Aortic Aneurysm

one-time

Male ages 60 to 80 years

Pulse Oximetry for Critical Congenital Heart Disease

Male or Female ages newborn to 2 months

HPLC (BIORAD KIT) for Thalassemia

Male or Female ages newborn to 2 months

Fluorescence Assay (PE Neonatal Kit) for G6PD Deficiency

Male or Female ages newborn to 2 months

Liver Ultrasound or AFP for Hepatocellular Carcinoma

every 6 months

Male or Female with cirrhosis and with metabolic diseases or non-alcoholic or alcoholic liver diseases, with family history of hepatocellular carcinoma, with prolonged heavy alcohol consumption, or ages 40 years with known hepatitis B infection

HPV Testing, VIA or Cytology for Cervical Cancer

every 3 years for cytology, every 5 years for HPV

Female ages 30 to 65 years

Mammography for Breast Cancer

every 1-2 years

Female ages 50 to 69 years

Screening for Gonorrhea and Chlamydia

High-risk asymptomatic, apparently healthy non-pregnant adolescents and adults

Screening for Dental Infections

Annual

Asymptomatic, apparently healthy adults

Screening for Thyroid Disease

Asymptomatic pregnant Filipino women

Otoacoustic Emissions, and Automated Auditory Brainstem Response for Hearing Loss Screening

Apparently healthy newborns

Tuning Fork Tests for Hearing Loss Screening

Asymptomatic apparently healthy school-aged children

Screening for Amblyopia

Asymptomatic, apparently healthy children

Screening for Ocular Pathology

Asymptomatic, apparently healthy infants

Screening for Strabismus

Asymptomatic apparently healthy children

Screening for Glaucoma

Annually

Asymptomatic, apparently healthy adults

Screening for Age-related Macular Degeneration

Every 1-3 years

Asymptomatic, apparently healthy adults aged >60 years with risk factors for age-related macular degeneration

Screening for Refractive errors

Varied

Asymptomatic, apparently healthy children

Screening for Refractive errors

Varied

Asymptomatic, apparently healthy adults

Weak recommendation

Weak recommendation means that trade-offs are less certain, either because of low quality evidence or because evidence suggests desirable and undesirable effects are closely balanced.

Test & Disease

Frequency

Target Population

History of High Risk Sexual Behavior

every visit

Male or Female ages 13 to 18

History of Unhealthy Alcohol Use

every visit

Male or Female ages 13 to 18 years

Standardized Questionnaire for Depression

every year

Male or Female aged 19 years and above

Standardized Questionnaire for Substance Use Disorders

once a year

Male or Female ages 13 to 18 years

Standardized Questionnaire for Anxiety among Adolescents

twice a year

Male or Female ages 13 to 18 years

Screening for Work-related Musculoskeletal Disorder

Asymptomatic, apparently healthy working adults

Screening for Prediabetes and Type 2 Diabetes Mellitus

Apparently healthy adults aged 40 years above, or younger if with risk factors

Mid-upper Arm Circumference or Weight for Height Z Scores for Acute Malnutrition

every visit

Male or Female ages 6 to 59 months

Red Reflex Test for Retinoblastoma

Male or Female aged 1 to 5 years

GALS/pGALS to Screen for Musculoskeletal Disease

Once a year

Asymptomatic, apparently healthy adults

GALS/pGALS to Screen for Musculoskeletal Disease

Once a year

Asymptomatic, apparently healthy children

Screening for Inadequate Physical Activity

Annual

Asymptomatic, apparently healthy adolescents

Screening for Malnutrition/Undernutrition

Asymptomatic, apparently healthy adults

Screening for Malnutrition/Undernutrition

Asymptomatic, apparently healthy adults

Lipid Profile Test for Lipid Disorder

every year

Male or Female ages 40 to 75 years with risk factors

HBA1C for Diabetes

Male or Female aged 40 years and above with risk factors

Screening for Latent TB

Asymptomatic, apparently healthy adults, who are at high risk for TB infection

Chest X-Ray for Pulmonary Tubercolosis

every year

Male or Female aged 19 years and above

EBV DNA or Nasopharyngoscopy for Nasopharyngeal Cancer

Male or Female aged 19 and above with a 1st degree relative with known nasopharyngeal cancer

PSA Determination or Digital Rectal Exam for Prostate Cancer

Biennial

Male ages 50 to 64 years

Low-Dose CT for Lung Cancer

annual

Male or Female aged 50 years and above with history of smoking or family history of lung cancer

Upper Gastrointestinal Series or Upper Endoscopy for Gastric Cancer

Male or Female aged 40 years and above with family history of gastric cancer, documented history of precancerous lesions for gastric cancer (i.e., atrophic gastritis, intestinal metaplasia), history of H. pylori infection, obesity, history of smoking or history of high consumption of salted food

Screening for Asymptomatic Bacteriuria

Asymptomatic, apparently healthy pregnant women

Screening for Hearing Loss (Adults)

Asymptomatic apparently healthy elderly adults

Screening for Fetal Aneuploidy

Asymptomatic pregnant women

Screening for Gestational Diabetes Mellitus

Asymptomatic pregnant women

Screening for Group B Streptococcus

Asymptomatic pregnant women

Screening for Maternal and Perinatal Outcomes for First Trimester

Asymptomatic pregnant Filipino women

Screening for Maternal and Perinatal Outcomes for Second Trimester

Asymptomatic pregnant Filipino women

Screening for Pre-eclampsia

Asymptomatic pregnant women

Screening for Risk for Pre-eclampsia

Asymptomatic pregnant women

Screening for Undernutrition (Pregnant Women)

Asymptomatic pregnant Filipino adolescent and adult women

Pneumatic Otoscopy for Hearing Loss Screening

Asymptomatic apparently healthy school-aged children

Please fill up the fields to view recommendations.

No results found.

Strong recommendation against

Strong recommendation means that desirable effects of intervention clearly outweigh undesirable effects.

Test & Disease

Target Population

Standardized Questionnaire for Developmental Delay

Male or Female ages 1 to 12 years

Screening for Osteoporosis

Asymptomatic, apparently healthy men at any age

Screening for Osteoporosis

Asymptomatic, apparently healthy women <65 years old

Screening for Hypo/Hypercalcemia

Asymptomatic, apparently healthy adults

Screening for Hypo/Hypercalcemia

Asymptomatic, apparently healthy adults

Screening for Hypo/Hypercalcemia

Asymptomatic, apparently healthy adults

Screening for Hyperuricemia

Asymptomatic, apparently healthy adults

Carotid Bruit Auscultation for Carotid Artery Stenosis

Male or Female aged 19 years and above

Pulse Palpation for Peripheral Arterial Disease

Male or Female aged 19 years and above

Pulse Palpation for Atrial Fibrillation

Male or Female aged 19 years and above

Serum Creatinine for Chronic Kidney Disease

Male or Female aged 19 years and above

Newborn Screening for Cystic Fibrosis

Male or Female ages newborn to 2 months

Newborn Screening for Sickle Cell Disease

Male or Female ages newborn to 2 months

Newborn Screening for Homocystinuria and Methionine Adenosyltransferase Deficiency

Male or Female ages newborn to 2 months.

Newborn Screening for Homocystinuria and Methionine Adenosyltransferase Deficiency

Male or Female ages newborn to 2 months

Newborn Screening for Tyrosinemia

Male or Female ages newborn to 2 months

Newborn Screening for Fatty Acid Oxidation Disorders

Male or Female ages newborn to 2 months

Newborn Screening for Fatty Acid Oxidation Disorders

Male or Female ages newborn to 2 months

Newborn Screening for Biotidinase Deficiency

Male or Female ages newborn to 2 months

Newborn Screening for Beta-Ketothiolase Deficiency

Male or Female ages newborn to 2 months

Newborn Screening for Holocarboxylase Synthetase Deficiency

Male or Female ages newborn to 2 months

Newborn Screening for Isovaleric Acidemia

Male or Female ages newborn to 2 months

Screening for Low Vitamin D

Asymptomatic, apparently healthy infants, children, and adults

Screening for Hepatitis C

Asymptomatic, apparently healthy adults

Screening for HIV

Asymptomatic, apparently healthy adolescents and adults

Resting ECG or Exercise ECG for Coronary Artery Disease

Male or Female aged 19 years and above

Resting Echocardiography for Coronary Artery Disease

Male or Female aged 19 years and above

Stress Echocardiography for Coronary Artery Disease

Male or Female aged 19 years and above

Carotid Ultrasound for Carotid Artery Stenosis

Male or Female aged 19 years and above

Doppler Ankle Brachial Index for Peripheral Arterial Disease

Male or Female aged 19 years and above

Ultrasonography for Abdominal Aortic Aneurysm

Female aged 19 years and above

12-Lead Electrocardiography for Atrial Fibrillation

Male or Female aged 19 years and above

Standardized Drug Tests for Substance Use Disorders

Male or Female aged 19 years and above

HPV Testing, VIA or Cytology for Cervical Cancer

Female ages 21 to 29 years

Screening for COVID-19

Asymptomatic, apparently healthy adults

Tandem Walking and Romberg’s Test for Vestibular Disorders

Asymptomatic apparently healthy children and adults (<60 years old)

Tandem Walking and Romberg’s Test for Vestibular Disorders

Asymptomatic apparently healthy elderly adults (>60 years old)

Fetal Heart Rate Monitoring for Prenatal/Antenatal Hearing Loss Screening

Asymptomatic apparently healthy pregnant women

Weak recommendation against

Weak recommendation means that trade-offs are less certain, either because of low quality evidence or because evidence suggests desirable and undesirable effects are closely balanced.

Test & Disease

Target Population

Standardized Questionnaire for Dementia

Male or Female aged 60 years and above

Screening for Sarcopenia

Asymptomatic, apparently healthy adults <60 years old

Fall Risk Evaluation to Screen for Predisposition to Fall

Asymptomatic, apparently healthy adults <60 years old

Screening for Chronic Kidney Disease

Asymptomatic, apparently healthy adults

Screening for Chronic Kidney Disease

Asymptomatic, apparently healthy adults

Screening for Chronic Kidney Disease

Asymptomatic, apparently healthy adults

Screening for High Climacteric Syndrome

Asymptomatic, apparently healthy Filipino women aged 45–55 years

Screening for High Climacteric Syndrome

Asymptomatic, apparently healthy Filipino women aged 45–55 years

Screening for High Climacteric Syndrome

Asymptomatic, apparently healthy Filipino women aged 45–55 years

Screening for Scoliosis

Asymptomatic, apparently healthy children

Screening for Inadequate Physical Activity

Asymptomatic, apparently healthy children

Standardized Screening Assessment for Risk of Musculoskeletal Injuries

Asymptomatic, apparently healthy children and adults

Screening for Malnutrition/Undernutrition

Asymptomatic, apparently healthy adults

Lipid Profile Test for Lipid Disorder

Male or Female ages 18 to 39 years

Hemoglobin/Hematocrit for Anemia

Male or Female aged 19 years and above

Screening for Latent TB

Asymptomatic, apparently healthy adults

Screening for Hepatitis A

Asymptomatic, apparently healthy adults

Screening for Syphilis

Asymptomatic, apparently healthy non-pregnant adolescents and adults

Chest X-Ray for Lung Cancer

Male or Female aged 19 years and above

Urinalysis for Chronic Kidney Disease

Male or Female aged 19 years and above

EBV DNA or Nasopharyngoscopy for Nasopharyngeal Cancer

Male or Female aged 19 and above

Liver Ultrasound or AFP for Hepatocellular Carcinoma

Male or Female aged 19 years and above

Low-Dose CT for Lung Cancer

Male or Female with low risk for cancer (less than 50 years old, non-smoker and no family history of lung cancer)

Upper Gastrointestinal Series or Upper Endoscopy for Gastric Cancer

Male or Female aged 19 and above without risk factors

Screening for Intestinal Parasitism

Asymptomatic, apparently healthy children and adults

Screening for Gonorrhea and Chlamydia

Asymptomatic, apparently healthy non-pregnant adolescents and adults

Screening for Asymptomatic Bacteriuria

Asymptomatic, apparently healthy adults

Screening for Differences in Timing of Sexual Maturity

Asymptomatic, apparently healthy adolescents

Screening for Cervical Length

Asymptomatic pregnant Filipino women

Screening for Iron Deficiency Anemia

Asymptomatic pregnant Filipino women

Pure Tone Audiometry for Hearing Loss Screening

Asymptomatic apparently healthy school-aged children

Phone-based Screening Audiometry for Hearing Loss Screening

Asymptomatic apparently healthy school-aged children

Screening for Cataract

Asymptomatic, apparently healthy adults

No Recommendation - Insufficient Evidence

Insufficient Evidence means Consensus Panel deemed that there was not enough evidence to make a decision.

Test & Disease

Target Population

Screening for Developmental Delay

Male or Female ages 1 to 12 years

Screening for Developmental Delay

Male or Female ages 1 to 12 years

Screening for Learning Disorders

Male or Female ages 1 to 12 years

Red Reflex Test for Retinoblastoma

Male or Female ages 1 to 12 years

Screening for Hearing Loss (Adults)

Asymptomatic apparently healthy adults less than 50 years old

No Recommendation - No Consensus Reached

No Consensus Reached means Consensus Panel were not able to reach consensus.

Test & Disease

Target Population

ENT Screening and Dental Check-Up for Oral Cancer

Male or Female aged 35 years and above

Recommendations for Recommendations Against No Recommendations

Strong recommendation

Strong recommendation means that desirable effects of intervention clearly outweigh undesirable effects.

Type of Vaccine

Frequency

Target Population

Cholera Vaccine for Adults

Asymptomatic apparently healthy adults traveling to cholera-endemic areas

HPV Vaccine for Adults (Updated)

Apparently healthy asymptomatic females

Inactivated Polio Vaccine for Children

Male or Female ages newborn to 1 year.

Measles-Containing Vaccine for Adults (Updated)

one series

Unvaccinated adult or non-pregnant aged 19 years and above

Measles-containing Vaccines for Children

Apparently healthy children

Pneumococcal Vaccine for Adults (Updated)

Apparently healthy adults

Rotavirus Vaccine for Infants

Apparently healthy infants starting at 6 weeks old

Tetanus Vaccine for Adults (Updated)

Every 10 years

Healthy adults with complete primary series

Varicella Vaccine for Children

Healthy children and adolescents

Weak recommendation

Weak recommendation means that trade-offs are less certain, either because of low quality evidence or because evidence suggests desirable and undesirable effects are closely balanced.

Type of Vaccine

Frequency

Target Population

BCG vaccine for Infants

Healthy infants

Haemophilus Influenzae B Vaccine Booster for Children

Healthy children who completed the primary series of Haemophilus influenzae B (Hib) vaccine

Haemophilus Influenzae B Vaccine for Adults

Adults with anatomical and functional asplenia

Hepatitis A Vaccine for Adults

0, and 6 months

Asymptomatic apparently healthy adults

Hepatitis A Vaccine for Children

Male or Female ages 1 to 12 years

Hepatitis B Vaccine Booster for Children

Healthy children and adolescents who completed at least a 3-dose primary vaccination series but did not seroconvert

Herpes Zoster Vaccine for Adults (Updated)

Apparently healthy elderly

HPV Vaccine for Adults (Updated)

Apparently healthy asymptomatic males

Human Papillomavirus Vaccine for Children

Female ages 9 to 18 years

Influenza Vaccine for Adults (Updated)

Annual

Healthy adults

Influenza Vaccine for Adults (Updated)

Annual

Pregnant women

Influenza Vaccine for Adults (Updated)

Annual

Elderly

Influenza Vaccine for Adults (Updated)

Annual

Healthcare workers

Influenza Vaccine for Children

annual

Male or Female ages 1 to 18 years

Japanese Encephalitis Vaccine for Adults

Asymptomatic apparently healthy adults

Japanese Encephalitis Vaccine for Children

Male or Female ages 1 to 18 years in high risk areas

Meningococcal Vaccine for Adults

Adults with high risk of contracting meningococcal disease

Meningococcal Vaccine for Adults

Adults with high risk of contracting meningococcal disease

Meningococcal Vaccine for Children

Male or Female ages 1 to 18 years

Meningococcal Vaccine for Children

Male or Female ages 1 to 18 years

Mumps-containing Vaccines for Children

Apparently healthy children

Oral Polio Vaccine for Children

Male or Female ages newborn to 1 year

Pertussis-containing Vaccine Booster for Children

Children and adolescents who completed the 3-dose primary DPT series

Pneumococcal Conjugate Vaccine Brands for Children

Apparently healthy children

Pneumococcal Vaccine for Adults (Updated)

Apparently healthy adults

Pneumococcal Vaccine for Adults (Updated)

Apparently healthy adults

Pre-exposure Rabies Vaccine for Adults

Healthcare workers with high risk of exposure to rabies

Pre-exposure Rabies Vaccine for Adults

Adults with high risk of exposure

Rabies Pre-exposure Prophylaxis (PrEP) for Children

Apparently healthy children and adolescents 5-18 years old with high risk of rabies

Tetanus Toxoid-containing Vaccine Booster for Children

Healthy infants and children who completed a 3-dose primary series of tetanus toxoid-containing vaccines

Tetanus Vaccine for Adults (Updated)

Pregnant women with unknown status or incomplete series

Tetanus Vaccine for Adults (Updated)

Each pregnancy

Pregnant women with complete primary series

Tetanus Vaccine for Adults (Updated)

Healthy adults with unknown status or incomplete series

Typhoid Vaccine for Adults (Updated)

Healthy adults

Typhoid Vaccine for Children

single dose

Male or Female ages 1 to 18 years

Varicella Vaccine for Children

Healthy children and adolescents

Please fill up the fields to view recommendations.

No results found.

Strong recommendation against

Strong recommendation means that desirable effects of intervention clearly outweigh undesirable effects.

Type of Vaccine

Target Population

Haemophilus Influenzae B Vaccine for Adults

Asymptomatic apparently healthy adults

Haemophilus Influenzae B Vaccine for Adults

Asymptomatic healthcare workers

Weak recommendation against

Weak recommendation means that trade-offs are less certain, either because of low quality evidence or because evidence suggests desirable and undesirable effects are closely balanced.

Type of Vaccine

Target Population

Cholera Vaccine for Adults

Asymptomatic apparently healthy adults

Cholera Vaccine for Adults

Asymptomatic healthcare workers

Haemophilus Influenzae B Vaccine for Adults

Pregnant women

HPV Vaccine for Adults (Updated)

Apparently healthy asymptomatic adults

HPV Vaccine for Adults (Updated)

Pregnant patients

Meningococcal Vaccine for Adults

Asymptomatic apparently healthy adults

Meningococcal Vaccine for Adults

Asymptomatic apparently healthy young adults

Monkeypox Vaccine for Adults

Apparently healthy adults

Monkeypox Vaccine for Adults

Adults with high risk of exposure to monkeypox

Pre-exposure Rabies Vaccine for Adults

Asymptomatic healthy adults

Typhoid Vaccine for Adults (Updated)

Healthcare workers

Varicella Vaccine for Adults

Asymptomatic apparently healthy adults

Varicella Vaccine for Adults

Asymptomatic healthcare workers

No Recommendation - Insufficient Evidence

Insufficient Evidence means Consensus Panel deemed that there was not enough evidence to make a decision.

Type of Vaccine

Target Population

HPV Vaccine for Adults (Updated)

Apparently healthy asymptomatic sex workers

Pneumococcal Vaccine for Adults (Updated)

Apparently healthy adults

Typhoid Vaccine for Adults (Updated)

Healthy adults

Recommendations for Recommendations Against No Recommendations

Strong recommendation

Strong recommendation means that desirable effects of intervention clearly outweigh undesirable effects.

Advice

Target Population

Brief interventions, Psychological/motivational Coaching, or Behavioral Counselling for Physical Activity

Male or Female aged 19 years and above ...

Brief interventions, Psychological/motivational Coaching, or Behavioral Counselling for Physical Activity

Male or Female ages 13 to 18 years...

Behavioral Counselling or Psychological/motivational Coaching for Healthy Nutrition

Male or Female aged 19 years and above ...

Behavioral Counselling or Psychological/motivational Coaching for Healthy Nutrition

Male or Female ages 13 to 18 years...

Nonpharmacologic Interventions for Internet Addiction

Male or Female ages 13 to 18 years ...

Nonpharmacologic Interventions (Counseling) for Smoking Cessation

Male or Female aged 19 years and above...

Nonpharmacologic Interventions (Counseling) for Smoking Cessation

Male or Female ages 13 to 18 years ...

Non-pharmacologic Interventions on Safe Sex for Preventing sexually transmitted infections, unintended pregnancy, unprotected intercourse, and to promote consistent condom use

Male or Female aged 19 years and above...

Non-pharmacologic Interventions on Safe Sex for Preventing sexually transmitted infections, unintended pregnancy, unprotected intercourse, and to promote consistent condom use

Male or Female ages 13 to 18 years ...

Weak recommendation

Weak recommendation means that trade-offs are less certain, either because of low quality evidence or because evidence suggests desirable and undesirable effects are closely balanced.

Advice

Target Population

Nonpharmacologic Interventions for Stress

Male or Female aged 19 years and above

Nonpharmacologic Interventions for Stress

Male or Female ages 13 to 18 years

Nonpharmacologic Interventions for Internet Addiction

Male or Female aged 19 years and above

Nonpharmacologic Interventions for Internet Addiction

Male or Female ages 13 to 18 years

Please fill up the fields to view recommendations.

No results found.

Strong recommendation against

Strong recommendation means that desirable effects of intervention clearly outweigh undesirable effects.

Advice

Target Population

Electronic Nicotine Delivery Systems (ENDS) for Smoking Cessation

Male or Female aged 19 years and above

Electronic Nicotine Delivery Systems (ENDS) for Smoking Cessation

Male or Female ages 13 to 18 years

Weak recommendation against

Weak recommendation means that trade-offs are less certain, either because of low quality evidence or because evidence suggests desirable and undesirable effects are closely balanced.

Advice

Target Population

Behavioral Counselling or Psychological/motivational Coaching for Healthy Nutrition

Male or Female ages 13 to 18 years